Obstructive Sleep Apnea and Metabolic Syndrome: Where is the Chicken? Where is the Egg? by Polotsky, MD, PhD, Vsevolod Y.
Thomas Jefferson University
Jefferson Digital Commons
Pulmonary and Critical Care Medicine,
Presentations and Grand Rounds Division of Pulmonary and Critical Care Medicine
11-5-2014
Obstructive Sleep Apnea and Metabolic
Syndrome: Where is the Chicken? Where is the
Egg?
Vsevolod Y. Polotsky, MD, PhD
Johns Hopkins University, vpolots1@jhmi.edu
Let us know how access to this document benefits you
Follow this and additional works at: http://jdc.jefferson.edu/pulmcritcaregrandrounds
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Pulmonary and Critical Care Medicine, Presentations and Grand Rounds by an authorized administrator of the Jefferson Digital Commons. For more
information, please contact: JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Polotsky, MD, PhD, Vsevolod Y., "Obstructive Sleep Apnea and Metabolic Syndrome: Where is the
Chicken? Where is the Egg?" (2014). Pulmonary and Critical Care Medicine, Presentations and Grand
Rounds. Presentation 114.
http://jdc.jefferson.edu/pulmcritcaregrandrounds/114
Obstructive Sleep Apnea and Metabolic Syndrome: 
Where is the Chicken? Where is the Egg ?
Vsevolod Y. Polotsky, M.D., Ph.D.
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine, 




• No financial relationships with 
commercial entities to disclose
• I will not reference an unlabeled/ 








TRACING OF OBSTRUCTIVE APNEAS DURING SLEEP 
PREVALENCE
AHI ≥ 5: 24% in men and 9% in women 
(Young et al., 1993)
30-60% in obese individuals 
(Vgontzas, 2000; Punjabi 2002; Young 1993 and 2002; 
Tufik 2010)

Sleep-Disordered Breathing and Mortality: a 
Prospective Cohort Study
Punjabi NM et al. PLoS Med. 2009 Aug;6(8):e1000132. Epub 2009 Aug 18. 
Marin JM, Carrizo SJ, Vicente E, Agusti AG.
Lancet. 2005 Mar 19-25;365(9464):1046-53. 
Current evidence suggests that increased
cardiovascular risk of OSA may be related
to the increased prevalence of the metabolic 
syndrome in patients with OSA
Current evidence suggests that increased
cardiovascular risk of OSA may be related
to the increased prevalence of the metabolic 
syndrome in patients with OSA
Metabolic Syndrome (NCEP, 2001 and AHA/NHLBI, 2004)
Any 3 of the following
• Abdominal obesity 
• Serum triglycerides > 150 mg/dl
• HDL-C  < 40 mg/dl in men and < 50 mg/dl in women
• BP > 130/85 (or treated for HTN) 
• Fasting blood glucose > 100 mg/dl (or Medx)
+ Non-alcoholic fatty liver disease
•Obstructive Sleep Apnea, Insulin 
Resistance and Type 2 Diabetes
• Obstructive Sleep Apnea and 
Dysregulation of Lipid Metabolism
• Obstructive Sleep Apnea and Fatty Liver
•Obstructive Sleep Apnea, Insulin 
Resistance and Type 2 Diabetes
• Obstructive Sleep Apnea and 
Dysregulation of Lipid Metabolism
• Obstructive Sleep Apnea and Fatty Liver

HOMA = G0xI0/22.5
Punjabi et al. Sleep-disordered breathing, glucose intolerance, 




















Prevalence of OSA in T2DM 
(adapted from Pamidi and Tasali, 
Front Neurol. 2012;3:126. Epub 2012 Aug 13)
CPAP effect 
• 9 small RCT (1 – 12 wks)
•in different population of apneics
• Different outcomes (SI, HbA1C, fasting 
blood glucose and insulin)
• 4 studies showed some improvement ,
5 showed none
CPAP effect
Chirinos et al. 
CPAP effect
New data from Punjabi and Tasali
presented at ATS 2014 indicate
significant improvement of insulin 
resistance with CPAP








Mouse Model of Intermittent Hypoxia
Intermittent Hypoxia is a Complex Stimulus: IH 







Polotsky et al. Sleep Med. 2006 Jan;7(1):7-16. 





































Liver Muscle Epididymal fat






































































































































Four weeks Four weeks
Intermittent Hypoxia Increases Insulin Resistance and Suppresses Insulin 
Secretion
Lee EJ et al. Eur J Appl Physiol., 2013, 113:467-78





































Liver Muscle Epididymal fat
Systemic Effects (Carotid bodies, SNS)
Reinke et al. J Appl Physiol 2011, 111:881-90
Carotid Body governs systemic 
responses to Intermittent Hypoxia 
Carotid Sinus Nerve Dissection
Lesske et al. Journal of  Hypertension. 1997. 15:1593-1603.
Carotid Body governs systemic 
















































































































Shin et al. J Appl Physiol. 2014 Oct 1;117(7):765-76.
CSND abolishes sympathetic activation in 
the liver
Shin et al. J Appl Physiol. 2014 Oct 1;117(7):765-76.
Carotid Body Governs Systemic 



























•Obstructive Sleep Apnea, Insulin 
Resistance and Type 2 Diabetes
• Obstructive Sleep Apnea and 
Dysregulation of Lipid Metabolism
• Obstructive Sleep Apnea and Fatty Liver
OSA  is Associated with Dyslipidemia
Relation of Sleep-disordered Breathing to Cardiovascular Disease Risk Factors: The 
Sleep Heart Health Study. Newman et al. Am J Epidemiol 2001;154:50–9.
CPAP and Plasma Lipids: 
Randomized Studies
Independent Association Between Nocturnal 
Intermittent Hypoxemia and Metabolic 
Dyslipidemia in Obstructive Sleep Apnea  
Trzepizur et al. Chest . 2013; 143:1584-9.
CPAP (2 months) and Postprandial Plasma Lipids: 






Phillips et al. AJRCCM . 2011; 184:355-361.

Intermittent Hypoxia increases VLDL levels
CIH for 12 weeks in C57BL/6J mice
Savransky V, Nanayakkara A, Li J, Bevans S, Smith PL, Rodriguez A, Polotsky VY. 2007. Am J Resp 















Intermittent Hypoxia and 
Adipose Tissue Lipolysis





































Liver Muscle Epididymal fat
Systemic Effects (Carotid bodies, SNS)

























Jun et al. Am J Physiol Endocrinol Metab. 2014 Oct. [Epub ahead of print]
In patients with sleep apnea nocturnal elevation of 



































Jun et al. Sleep. 2011; 33:783-90.
Intermittent Hypoxia and Lipoprotein 
Clearance





































Liver Muscle Epididymal fat
Tissue Specific Effects (Hypoxia inducible factors, etc))
















Intermittent Hypoxia Decreases  Lipoprotein 
















Drager et al. Eur Heart J . 2012; 33:783-90.
Angiopoietin-like Protein 4 Rapidly Inactivates 
Lipoprotein Lipase (LPL)



























































Intermittent Hypoxia Increases Adipose Angptl4
Drager et al. Eur Heart J . 2012; 33:783-90.
Sham
Angptl4 Ab prevent CIH-induced dyslipidemia
Drager, Yao et al. AJRCCM 2013; 188:240-8
Angptl4 Ab prevent CIH-induced atherosclerosis
Drager, Yao et al. AJRCCM 2013; 188:240-8
In obese patients, expression of Angptl4 in subcutaneous fat





























Drager, Yao et al. AJRCCM 2013; 188:240-8
Intermittent Hypoxia and Lipoprotein Clearance
•  Lipoprotein clearance by up-regulating adipose Angptl4,
a potent inhibitor of lipoprotein lipase 
• Adipose tissue hypoxia may play a role in cardiovascular
morbidity and mortality of OSA 
•OSA and Intermittent Hypoxia
•Intermittent Hypoxia, Insulin 
Resistance and Type 2 Diabetes
• Intermittent Hypoxia and Dysregulation
of Lipid Metabolism
• Intermittent Hypoxia and Fatty Liver






OSA and Non-Alcoholic Fatty Liver
OSA and Non-Alcoholic Fatty Liver
Polotsky et al.  Am J Respir Crit Care Med, 179 (2009), pp. 228–234
BMI 45, no OSA Severe OSA
BMI 45, no OSA Severe OSA





Intermittent Hypoxia Causes 
Steatohepatitis and Liver Fibrosis
What are the mechanisms ?
Lysyl oxidase (LOX))
• Secreted amine oxidase.
• Catalyzes formation of covalent bonds between 
collagen fibers.
• Tissue hypoxia (via
HIF-1) increases
expression of LOX.
Kagan et al., 2003.
Erler et al., 2006; Higgins et al., 2007.





































Liver Muscle Epididymal fat
Tissue Specific Effects (Hypoxia inducible factors, etc))
Intermittent  hypoxia up-regulates collagen 
cross-linking enzyme lysyl oxidase in hepatocytes









































Mesarwi et al. Manuscript in preparation
LOX secreted by hepatocytes in hypoxic cross-links 
collagen
16% Oxygen 1% Oxygen 1% Oxygen with LOX inhibitor
10 µm
LOX secreted by hepatocytes in hypoxic cross-links 
collagen
Mesarwi et al. Manuscript in preparation
Study design
• 35 consecutive patients recruited from the Bariatric Surgery 
clinic at Johns Hopkins Bayview Medical Center.
• Polysomnogram
• Serum LOX checked the morning after PSG.
• Liver biopsies analyzed for steatosis, fibrosis, and NAFLD 
activity score.
• Patients categorized by presence/absence of hepatic 
fibrosis.
OSA       IH       LOX       Liver Fibrosis     
R = 0.51, p < 0.002
Mesarwi et al. Manuscript in preparation
OSA       IH       LOX       Liver Fibrosis     
Mesarwi et al. Manuscript in preparation
OSA       IH       LOX       Liver Fibrosis     
Mesarwi et al. Manuscript in preparation
Baseline BaselineNo treatment Baseline CPAP
Mechanisms of Liver Fibrosis during IH: Hypothesis
1. IH induces liver tissue hypoxia
2. Liver tissue hypoxia up-regulates HIF-1
3. HIF-1 up-regulates LOX
4. LOX cross-links collagen resulting in liver fibrosis
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